Literature DB >> 6135428

Pharmacology of the specific histamine H1-antagonist astemizole.

F H Awouters, C J Niemegeers, P A Janssen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135428

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


× No keyword cloud information.
  7 in total

Review 1.  Assessing the cardiac safety of ebastine. Prologue.

Authors:  D J Roberts
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

2.  Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain.

Authors:  R Oishi; S Shishido; M Yamori; K Saeki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-02       Impact factor: 3.000

3.  The pharmacological profile of a specific, safe, effective and non-sedative anti-allergic, astemizole.

Authors:  C J Niemegeers; F Awouters; P A Janssen
Journal:  Agents Actions       Date:  1986-04

4.  The effect of cetirizine and loratadine on codeine-induced histamine release in human skin in vivo assessed by cutaneous microdialysis.

Authors:  M Perzanowska; D Malhotra; S P Skinner; J P Rihoux; A P Bewley; L J Petersen; M K Church
Journal:  Inflamm Res       Date:  1996-09       Impact factor: 4.575

Review 5.  Astemizole. A nonsedating antihistamine with fast and sustained activity.

Authors:  M M Janssens
Journal:  Clin Rev Allergy       Date:  1993

6.  The time course of action of three differing doses of noberastine, a novel H1-receptor antagonist, on histamine-induced skin wheals and the relationship to plasma drug concentrations in normal human volunteers.

Authors:  R Wood-Baker; M B Emanuel; K Hutchinson; P H Howarth
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

Review 7.  Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-07       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.